Current findings for recurring mutations in acute myeloid leukemia
2011

Recurring Mutations in Acute Myeloid Leukemia

Sample size: 281 publication Evidence: moderate

Author Information

Author(s): Takahashi Shinichiro

Primary Institution: Kitasato University Graduate School of Medical Sciences

Hypothesis

The review aims to summarize current findings regarding the identification of gene mutations in acute myeloid leukemia (AML).

Conclusion

The identification of novel genetic mutations in AML has advanced our understanding of the disease and its treatment.

Supporting Evidence

  • Mutations in Dnmt3a were found in 22.1% of AML patients.
  • TET2 mutations were detected in 23% of cytogenetically normal AML patients.
  • IDH1 mutations were associated with a higher risk of relapse and shorter overall survival.
  • NPM1 mutations were found in 27.5-35.2% of AML patients.
  • ASXL1 mutations were present in 10.8% of AML patients.
  • WT1 mutations were identified in 8.3-10.7% of cytogenetically normal AML patients.

Takeaway

Scientists found that certain gene changes happen often in a type of blood cancer called acute myeloid leukemia, which helps doctors understand how to treat it better.

Methodology

The review discusses findings from various studies that used advanced DNA sequencing techniques to identify mutations in AML patients.

Limitations

The review primarily focuses on unclassified mutations and does not provide exhaustive details on all genetic alterations in AML.

Participant Demographics

The review includes data from multiple studies involving AML patients, with a significant focus on those with normal cytogenetics.

Statistical Information

P-Value

p < 0.001

Statistical Significance

p < 0.001

Digital Object Identifier (DOI)

10.1186/1756-8722-4-36

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication